Affiliation:
1. Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska, USA
2. Department of Surgery, School of Medicine, and Mouse Biology Program, University of California Davis , California, USA
Abstract
Abstract
The HIV-1 often evades a robust antiretroviral-mediated immune response, leading to persistent infection within anatomically privileged sites including the CNS. Continuous low-level infection occurs in the presence of effective antiretroviral therapy (ART) in CD4+ T cells and mononuclear phagocytes (MP; monocytes, macrophages, microglia, and dendritic cells). Within the CNS, productive viral infection is found exclusively in microglia and meningeal, perivascular, and choroidal macrophages. MPs serve as the principal viral CNS reservoir. Animal models have been developed to recapitulate natural human HIV-1 infection. These include nonhuman primates, humanized mice, EcoHIV, and transgenic rodent models. These models have been used to study disease pathobiology, antiretroviral and immune modulatory agents, viral reservoirs, and eradication strategies. However, each of these models are limited to specific component(s) of human disease. Indeed, HIV-1 species specificity must drive therapeutic and cure studies. These have been studied in several model systems reflective of latent infections, specifically in MP (myeloid, monocyte, macrophages, microglia, and histiocyte cell) populations. Therefore, additional small animal models that allow productive viral replication to enable viral carriage into the brain and the virus-susceptible MPs are needed. To this end, this review serves to outline animal models currently available to study myeloid brain reservoirs and highlight areas that are lacking and require future research to more effectively study disease-specific events that could be useful for viral eradication studies both in and outside the CNS.
Publisher
Oxford University Press (OUP)
Subject
Cell Biology,Immunology,Immunology and Allergy
Reference128 articles.
1. Antiretroviral therapy and management of HIV infection;Volberding;Lancet,2010
2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials;Cahn;Lancet,2019
3. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells;Siliciano;Nat Med,2003
4. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy;Chun;Proc Natl Acad Sci USA,1997
5. Persistent HIV-1 replication maintains the tissue reservoir during therapy;Lorenzo-Redondo;Nature,2016